Alkermes Overview

  • Founded
  • 1987
Founded
  • Status
  • Public
  • Employees
  • 2,211
Employees
  • Stock Symbol
  • ALKS
Stock Symbol
  • Investments
  • 13
  • Share Price
  • $29.30
  • (As of Monday Closing)

Alkermes General Information

Description

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Contact Information

Formerly Known As
Antler Science Two
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • Connaught House
  • 1 Burlington Road
  • Dublin D04 C5Y6
  • Ireland
+353 (01) 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alkermes Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.30 $30.00 $21.24 - $33.00 $4.79B 163M 1.55M -$0.38

Alkermes Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 4,141,306 3,620,812 2,991,254 2,919,237
Revenue 1,200,866 1,173,751 1,038,756 1,170,947
EBITDA 20,037 48,157 (12,938) (116,931)
Net Income (61,654) (48,169) (110,861) (196,620)
Total Assets 1,977,845 2,024,484 1,949,730 1,805,403
Total Debt 415,329 416,206 410,157 290,946
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alkermes Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, d
Pharmaceuticals
Dublin, Ireland
2,211 As of 2021
00.000
000000000 00.000

0000 000

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
000000000000000
Monmouth Junction, NJ
000 As of 0000
000000000 -

000000 0

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o
0000 000000000
Tokyo, Japan
00000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alkermes Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tris Pharma Private Debt Financed Monmouth Junction, NJ 000 000000000 -
000000 00000000 Corporation Tokyo, Japan 00000 00.000 00000000 00.000
000000000000 00000 Corporate Backed or Acquired Boca Raton, FL 000000&0
00000 Corporation Mumbai, India 00000 00000000
000000 00000000000 Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
You’re viewing 5 of 26 competitors. Get the full list »

Alkermes Patents

Alkermes Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210371486-A1 Il-2 fusion polypeptide compositions and methods of making and using the same Pending 11-May-2020 000000000
US-20210347837-A1 Immunostimulatory agents in combination with angiogenesis inhibitors Pending 15-Apr-2020 00000000000
US-20210238177-A1 Crystalline forms of 3-((1r,5s,9r)-9-ethoxy-3-azabicyclo[3.3.1]nonan-9-yl)-benzamide and salt forms thereof Pending 04-Feb-2020 0000000000
US-20210253631-A1 Methods of purification Pending 24-Jan-2020 000000000
US-20210155636-A1 Substituted macrocyclic compounds and related methods of treatment Pending 25-Nov-2019 C07D498/08
To view Alkermes’s complete patent history, request access »

Alkermes Executive Team (35)

Name Title Board Seat Contact Info
Richard Pops Chief Executive Officer & Chairman
Iain Brown Chief Financial Officer
James Frates Chief Financial Officer, Finance & Senior Vice President
Blair Jackson Executive Vice President & Chief Operating Officer
Michael Landine Senior Vice President, Corporate Development
You’re viewing 5 of 35 executive team members. Get the full list »

Alkermes Board Members (16)

Name Representing Role Since
Brian Mckeon Self Board Member 000 0000
Cato Laurencin Ph.D Alkermes Board Member 000 0000
David Anstice Self Board Member 000 0000
David Daglio Alkermes Board Member 000 0000
Emily Alva Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Alkermes Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alkermes Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Investments & Acquisitions (13)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 25-Nov-2019 0000000000 00000 Drug Discovery 00000 000
0000000 00000 25-Aug-2014 00000 0000 0000 Drug Delivery 000000 00
0000000000000 26-Nov-2013 00000 0000 000.00 Drug Discovery 00000 000
0000000 00000 11-Sep-2013 00000 0000 0000 Drug Delivery 000000 00
Acceleron Pharma 23-Dec-2011 Later Stage VC 000.00 Drug Discovery 0000000 0
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Alkermes Exits (8)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 25-Aug-2014 00000 00000 00 0000 Completed
  • 12 buyers
0000000 0000000000 11-Sep-2013 00000 00000 00 0000 Completed
  • 6 buyers
000000000 000000 23-Dec-2011 00000 00000 00 000.00 Completed
  • 15 buyers
0000000 0000000000 12-Jul-2011 00000 00000 00 0000 Completed
  • 4 buyers
Acceleron Pharma 15-Dec-2009 Later Stage VC 0000 Completed
You’re viewing 5 of 8 exits. Get the full list »